Cytokinetics | CYTK - Sales Revenues

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
74.33

Cytokinetics reported $19.35M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Arca Biopharma 0 0 Mar/2025
Bayer EUR 13.41B 1.97B Mar/2026
Biogen USD 2.25B 30M Mar/2026
Brainstorm Cell Therapeutics 0 0 Mar/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cytokinetics USD 19.35M 1.59M Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Geron USD 51.84M 3.82M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026